लोड हो रहा है...
Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients
Dr Jordi Bruix* speaks to Laura Dormer, Editorial Director: Dr Jordi Bruix is the Head of the Barcelona Clinic Liver Cancer (BCLC) group at the Hospital Clinic (University of Barcelona, Spain) and Director of the Network for Research in Liver and Digestive Disease (CIBEREHD) in the Spanish Research...
में बचाया:
| में प्रकाशित: | Hepat Oncol |
|---|---|
| मुख्य लेखक: | |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Future Medicine Ltd
2016
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6095319/ https://ncbi.nlm.nih.gov/pubmed/30191039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2016-0007 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|